Last reviewed · How we verify
NCT05164406
Impact of Blood Salvage Therapy on Outcomes After Oncologic Liver Surgery
trial testing Blood salvage therapy in Liver Neoplasms in 106 participants. Completed in 28 February 2021.
1 August 2019
Quick facts
| Lead sponsor | Université de Sherbrooke |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 106 |
| Start date | 1 January 2018 |
| Primary completion | 1 August 2019 |
| Estimated completion | 28 February 2021 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Blood salvage therapy
Conditions studied
- Liver Neoplasms — all drugs for Liver Neoplasms →
Sponsor
Université de Sherbrooke — full company profile →
Who can join
Adults 18 to 100, any sex, with Liver Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A before and after trial comparing the systematic use of blood salvage therapy with leucocyte filter during oncologic liver resections. Recurrence, survival, allogenic transfusion rates and surgical outcomes are compared with a representative historic cohort.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Cell salvage for minimising perioperative allogeneic blood transfusion in adults undergoing elective surgery.
Lloyd TD, Geneen LJ, Bernhardt K, McClune W, et al · · 2023 · cited 20× · PMID 37681564 · DOI 10.1002/14651858.cd001888.pub5
Verify or expand the search:
- PubMed search for NCT05164406
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Liver Neoplasms
Currently open trials in the same condition.
- NCT07377487 — TheraSphere Japan Pre-Market Study · NA · recruiting
- NCT07473687 — Feasibility Study of Non-Contact Imaging-Based Physiological Monitoring in the Operating Room · recruiting
- NCT07227012 — Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatmen · Phase 1, PHASE2 · recruiting
- NCT07378709 — Exploratory Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma · recruiting
- NCT06261814 — Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors · Phase 2 · recruiting
Other Université de Sherbrooke trials
Trials by the same sponsor.
- NCT07524764 — Female Reproductive Health in Canadian Armed Forces · not yet recruiting
- NCT07511842 — REST-Knee: A Pilot RCT of 72-Hour Knee Immobilization and Pain Outcomes · NA · recruiting
- NCT07360587 — Thyroid Artery Embolization for the Treatment of Compressive Goiters. · NA · recruiting
- NCT07396857 — The Role of EDHFs on Blood Pressure Following a Bout of Prolonged Sitting · NA · recruiting
- NCT07122531 — Recovery With Exogenous Ketones and Antipsychotics · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05164406 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Université de Sherbrooke
- Last refreshed: 31 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05164406.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing